{'52WeekChange': 'Infinity',
 'SandP52WeekChange': None,
 'address1': '2929 Arch Street',
 'address2': 'Suite 600',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 12.34,
 'askSize': 1300,
 'averageDailyVolume10Day': 145025,
 'averageVolume': 173211,
 'averageVolume10days': 145025,
 'beta': None,
 'beta3Year': None,
 'bid': 11.75,
 'bidSize': 1000,
 'bookValue': -6.776,
 'category': None,
 'circulatingSupply': None,
 'city': 'Philadelphia',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 12.95,
 'dayLow': 12.18,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': None,
 'enterpriseToRevenue': None,
 'enterpriseValue': 165576832,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 10.234571,
 'fiftyTwoWeekHigh': 19.63,
 'fiftyTwoWeekLow': 5.51,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 3937734,
 'forwardEps': -1.94,
 'forwardPE': -6.3608246,
 'fromCurrency': None,
 'fullTimeEmployees': 29,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.14292,
 'heldPercentInstitutions': 0.68024004,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/cabalettabio.com',
 'longBusinessSummary': 'Cabaletta Bio, Inc., a clinical-stage biotechnology '
                        'company, focuses on the discovery and development of '
                        'engineered T cell therapies for patients with B '
                        'cell-mediated autoimmune diseases. Its proprietary '
                        'technology utilizes chimeric autoantibody receptor '
                        '(CAAR) T cells that are designed to selectively bind '
                        'and eliminate B cells, which produce disease-causing '
                        "autoantibodies or pathogenic B cells. The company's "
                        'lead product candidate is DSG3-CAART, which is in '
                        'Phase I clinical trial for the treatment of mucosal '
                        'pemphigus vulgaris, an autoimmune blistering skin '
                        'disease, and Hemophilia A with Factor VIII '
                        'alloantibodies. Its product candidate pipeline also '
                        'include MuSK-CAART, a preclinical stage product to '
                        'treat a subset of patients with myasthenia gravis; '
                        'FVIII-CAART, a discovery stage product to treat a '
                        'subset of patients with Hemophilia A; and '
                        'DSG3/1-CAART, a discovery stage product for the '
                        'treatment of mucocutaneous pemphigus vulgaris. '
                        'Cabaletta Bio, Inc. has a collaboration with the '
                        'University of Pennsylvania; and research agreement '
                        'with The Regents of the University of California. The '
                        'company was formerly known as Tycho Therapeutics, '
                        'Inc. and changed its name to Cabaletta Bio, Inc. in '
                        'August 2018. Cabaletta Bio, Inc. was founded in 2017 '
                        'and is headquartered in Philadelphia, Pennsylvania.',
 'longName': 'Cabaletta Bio, Inc.',
 'market': 'us_market',
 'marketCap': 296579552,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_590735322',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -20896000,
 'nextFiscalYearEnd': 1640908800,
 'open': 12.74,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '267 759 3100',
 'previousClose': 12.89,
 'priceHint': 2,
 'priceToBook': None,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 12.95,
 'regularMarketDayLow': 12.18,
 'regularMarketOpen': 12.74,
 'regularMarketPreviousClose': 12.89,
 'regularMarketPrice': 12.74,
 'regularMarketVolume': 133497,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 24034000,
 'sharesPercentSharesOut': 0.051599998,
 'sharesShort': 1240361,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 119127,
 'shortName': 'Cabaletta Bio, Inc.',
 'shortPercentOfFloat': 0.0646,
 'shortRatio': 4.76,
 'startDate': None,
 'state': 'PA',
 'strikePrice': None,
 'symbol': 'CABA',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -10.966,
 'twoHundredDayAverage': 10.734461,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '6fe46e50-561f-3aea-a102-2503a6e5bebe',
 'volume': 133497,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.cabalettabio.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '19104'}